Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.
Volatility & Risk
Vivos Therapeutics has a beta of 6.37, indicating that its stock price is 537% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Profitability
This table compares Vivos Therapeutics and West Pharmaceutical Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| West Pharmaceutical Services | 18.81% | 21.78% | 15.99% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.09 | -$21.17 million | ($1.90) | -0.04 |
| West Pharmaceutical Services | $3.07 billion | 9.45 | $493.70 million | $8.91 | 46.82 |
West Pharmaceutical Services has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 1.4% of Vivos Therapeutics shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Vivos Therapeutics and West Pharmaceutical Services, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| West Pharmaceutical Services | 0 | 1 | 13 | 0 | 2.93 |
Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 3,306.33%. West Pharmaceutical Services has a consensus target price of $424.67, suggesting a potential upside of 1.79%. Given Vivos Therapeutics’ higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than West Pharmaceutical Services.
Summary
West Pharmaceutical Services beats Vivos Therapeutics on 11 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics is a medical technology company focused on treatments for sleep-disordered breathing, including obstructive sleep apnea. The company works with dental providers to offer non-surgical approaches intended to improve patients’ airways and breathing during sleep. Its Vivos System combines proprietary oral appliances with treatment protocols used by trained dental professionals. The company also provides education and support to providers who offer its therapies. Based in Littleton, Colorado, Vivos primarily serves patients through a network of participating dental practices.
About West Pharmaceutical Services
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
